A Phase 3 Multicentre Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer

Project: Research

Project Description

NMA Reference Number: HREC/16/SVHM/73
SSA Reference Number: SSA/16/MonH/350
Monash Health HREC Ref: RES-16-0000520X
StatusActive
Effective start/end date25/03/1924/03/24

Keywords

  • clinical trial
  • phase 3 study
  • treatment efficacy
  • lung cancer